Palvella Therapeutics (PVLA, Financial) has successfully secured a new patent from the United States Patent and Trademark Office (USPTO), further enhancing its intellectual property portfolio. The patent, numbered 12,268,673, covers Palvella's leading product candidate, QTORIN 3.9% rapamycin anhydrous gel. This development is a significant milestone in the company's efforts to address rare skin conditions.
The newly issued patent encompasses the anhydrous compositions of mTOR inhibitors and details their methods of use. This broadens the protection for the QTORIN rapamycin gel, particularly in treating microcystic lymphatic malformations (LMs) and potentially other rare skin diseases.
This advancement underscores Palvella Therapeutics’ commitment to pioneering new therapies targeted at rare dermatological conditions, reinforcing their strategic focus on expanding their intellectual property to support innovative treatments.
